Novavax to Report Second Quarter 2026 Financial Results on August 6, 2026
Rhea-AI Summary
Novavax (Nasdaq: NVAX) will release its second quarter 2026 financial results before U.S. market open on Thursday, August 6, 2026, and will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and operational highlights.
Investors can join via live webcast at ir.novavax.com/events or by phone using U.S. dial-in (+1) 888-880-3330 or international dial-in (+1) 646-357-8766. A replay will be available online and by phone at (+1) 800-770-2030 (U.S.) or (+1) 609-800-9909 (international) with passcode 9097916# starting about two hours after the event.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference call details: | |
Date: | August 6, 2026 |
Time: | 8:30 a.m. ET |
URL to register phone: | |
Dial-in number: | (+1) 888-880-3330 ( |
Webcast: | The live webcast can be accessed at ir.novavax.com/events |
- Participants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.
- Participants can also dial direct to be entered into the call by an operator and will be prompted to request to join the Novavax, Inc. call.
- To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled start time.
A replay of the webcast will be available at ir.novavax.com/events and over the phone approximately two hours after the event:
Replay dial-in number: | (+1) 800-770-2030 ( |
Passcode: | 9097916# |
About Novavax
Novavax, Inc. (Nasdaq: NVAX) tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including its Matrix-M® adjuvant and protein-based nanoparticles. The Company's corporate growth strategy is designed to deliver value via three key strategic pillars: partnering its technology, capital-efficient research and development (R&D) innovation and a lean and efficient operating model. This includes maximizing impact through partnerships for its marketed products (Nuvaxovid™, R21/Matrix-M™), Matrix technology and R&D assets. Please visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Naina Zaman
844-668-2829
ir@novavax.com
Media
Yvonne Sprow
844-264-8571
media@novavax.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-report-second-quarter-2026-financial-results-on-august-6-2026-302838333.html
SOURCE Novavax, Inc.